Stockhub

Patrys Limited: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 September 2022

  • curprev 18:2918:29, 23 September 2022 95.149.241.133 talk 874 bytes +874 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that..."
Retrieved from "https://stockhub.co/research/Patrys_Limited"